Risk factor
Considerable default risk
Profitability factor
Greatly undervalued vs peers
About
Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy. As of December 2, 2021, Cassiopea S.p.A. operates as a subsidiary of Cosmo Pharmaceuticals N.V.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is 'cheap' on EV/EBITDA.